Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1990;21:1589-1593

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lyden, P. D.
Right arrow Articles by Zivin, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lyden, P. D.
Right arrow Articles by Zivin, J. A.

Stroke, Vol 21, 1589-1593, Copyright © 1990 by American Heart Association


ARTICLES

Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected] [published erratum appears in Stroke 1991 Feb;22(2):285]

PD Lyden, KP Madden, WM Clark, KC Sasse and JA Zivin
Department of Neurology, Veterans Administration Medical Center, San Diego, CA 92161.

We studied thrombolysis in an animal model of embolic stroke to determine the safety of tissue plasminogen activator and streptokinase. We occluded the middle cerebral arteries of 137 rabbits with radiolabeled blood clots and administered tissue plasminogen activator (n = 49), streptokinase (n = 40), or saline (n = 48) at various times after embolization. We assessed the rate of thrombolysis and cerebral hemorrhage 24 hours later. Both drugs were very effective in producing thrombolysis. Compared with saline, streptokinase caused a significant increase in the rate of cerebral hemorrhage (p less than 0.05), but tissue plasminogen activator did not. We conclude that thrombolytic therapy for acute stroke should be safer with tissue plasminogen activator than with streptokinase.


This article has been cited by other articles:


Home page
StrokeHome page
P. A. Lapchak, M.-K. Han, K. F. Salgado, J. Streeter, and J. A. Zivin
Safety Profile of Transcranial Near-Infrared Laser Therapy Administered in Combination With Thrombolytic Therapy to Embolized Rabbits
Stroke, November 1, 2008; 39(11): 3073 - 3078.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
R. Jahan, D. Stewart, H. V. Vinters, W. Yong, F. Vinuela, P. Vandeberg, and V. J. Marder
Middle Cerebral Artery Occlusion in the Rabbit Using Selective Angiography: Application for Assessment of Thrombolysis
Stroke, May 1, 2008; 39(5): 1613 - 1615.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. A. Lapchak, D. M. Araujo, D. Song, and J. A. Zivin
The Nonpeptide Glycoprotein IIb/IIIa Platelet Receptor Antagonist SM-20302 Reduces Tissue Plasminogen Activator-Induced Intracerebral Hemorrhage After Thromboembolic Stroke
Stroke, January 1, 2002; 33(1): 147 - 152.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
D. F. Chapman, P. Lyden, P. A. Lapchak, S. Nunez, H. Thibodeaux, and J. Zivin
Comparison of TNK With Wild-Type Tissue Plasminogen Activator in a Rabbit Embolic Stroke Model
Stroke, March 1, 2001; 32(3): 748 - 752.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
A C Pereira, P J Martin, and E A Warburton
Thrombolysis in acute ischaemic stroke
Postgrad. Med. J., March 1, 2001; 77(905): 166 - 171.
[Full Text]


Home page
StrokeHome page
P. A. Lapchak, D. F. Chapman, and J. A. Zivin
Pharmacological Effects of the Spin Trap Agents N-t-Butyl-Phenylnitrone (PBN) and 2,2,6,6-Tetramethylpiperidine-N-Oxyl (TEMPO) in a Rabbit Thromboembolic Stroke Model : Combination Studies With the Thrombolytic Tissue Plasminogen Activator
Stroke, January 1, 2001; 32(1): 147 - 153.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
Chest, January 1, 2001; 119(1_suppl): 300S - 320S.
[Full Text] [PDF]


Home page
StrokeHome page
P. A. Lapchak, D. F. Chapman, J. A. Zivin, and C. Y. Hsu
Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)-Induced Hemorrhage After Thromboembolic Stroke Editorial Comment
Stroke, December 1, 2000; 31(12): 3034 - 3040.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
J. A. Zivin
Thrombolytic stroke therapy: Past, present, and future
Neurology, July 1, 1999; 53(1): 14 - 14.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. R. Frankel, W. M. Clark, P. D. Lyden, K. P. Madden, J. A. Zivin, M. S. Firstenberg, M. Hommel, C. Cornu, and F. Boutitie
Thrombolytic Therapy in Acute Ischemic Stroke
N. Engl. J. Med., January 2, 1997; 336(1): 65 - 67.
[Full Text]


Home page
StrokeHome page
W. D. Dietrich, L. P. Miller, R. Prado, S. Dewanjee, N. Alexis, M. K. Dewanjee, and H. Gruber
Acadesine Reduces Indium-Labeled Platelet Deposition After Photothrombosis of the Common Carotid Artery in Rats
Stroke, January 1, 1995; 26(1): 111 - 116.
[Abstract] [Full Text]